- Shengnuo Biotech has gained a high reputation and recognition in the field of peptide drug R&D and production, and has played an important role in the development and industrialization of innovative peptide drugs in my country.
- Recently, Shengnuo Biotech pharmaceuticals made an initial public offering of new shares and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The raised funds are planned to be used in the “395 kg peptide API production line project” and so on.
- Possess rich technology accumulation
Shengnuo Biotech has gained a high reputation and recognition in the field of peptide drug R&D and production, and has played an important role in the development and industrialization of innovative peptide drugs in my country.
Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “Shengnuo Biotech”, 688117.SH) is one of the earliest established professional peptide drug manufacturers in China. After years of accumulation of experience in peptide drug research and development, production and industrialization development, The company has become one of the few domestic peptide drugs in the field of peptide drug development, production and sales of the entire industrial chain layout of the company. It is one of the most powerful peptide drug synthesis and production technology platforms in China, and it is also a global market for peptide generic drugs. One of the competitors.
Recently, Shengnuo Biotech pharmaceuticals made an initial public offering of new shares and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. The raised funds are planned to be used in the “395 kg peptide API production line project” and so on.
Industry-leading number of approved preparations
It is expected to use the new product to overtake the car
According to QYResearch statistics, the global peptide drug market scale increased from US$15.2 billion to US$28.5 billion from 2010 to 2018, with a compound annual growth rate of 8.17%. Compared with the total scale of the global pharmaceutical market, the proportion is low and the growth rate is high, and the market potential is huge. The peptide drug market in my country started late, but it has developed rapidly. From 2009 to 2017, sales rose from 5.6 billion yuan to 29.56 billion yuan, with an average annual compound growth rate of 23.12%, much higher than the global growth rate.
Shengnuo Biotech is a high-tech enterprise with core peptide synthesis and modification technologies. It has advanced and efficient peptide drug technology research and development and large-scale production capabilities. It has gained high popularity and recognition in the field of peptide drug research and development and production.
New drug research and development companies and scientific research institutions have provided pharmaceutical research and customized production services for more than 30 projects. Among them, one innovative peptide drug has been approved and entered the commercialization stage, and another seven innovative peptide drugs have entered the clinical trial stage, which are my country’s peptide drugs. The research and development and industrialization of similar innovative drugs play an important role.
Shengnuo Biotechtech selects peptide generic drugs with large market capacity and strong market competitiveness at home and abroad for research and development, and has mastered the large-scale production technology of 15 types of APIs, of which 7 varieties have obtained domestic production approvals, 8 Two varieties have been registered in the United States DMF (activated state), and the eight peptide preparation varieties developed by extension have obtained 12 domestic production approvals. The products cover various fields where peptide drugs play an important role.
The number of approved preparation varieties and dosage forms of peptide drug companies reflects the company’s long-term competitiveness in the industry. The number of varieties and dosage form approvals of Shengnuo Biotechlogical are among the top three in China. The number of peptide APIs and the ability to develop new products make the company’s preparation business have great development potential. It has made breakthroughs in individual new product markets, such as enfuvirtide injections. The liquid obtained the only domestic production approval; Carbetocin injection has a domestic market share of more than 20% in 2019, ranking second.
From the perspective of domestic competition, most local preparation companies lack advanced peptide synthesis technology.
In the future, as the difficulty of peptide drug imitation increases, a small number of companies with leading peptide drug research and development capabilities can control new products by imitating patented varieties that have recently expired.
Supply of raw materials, develop a variety of dosage forms, monopolize the incremental market of generic drugs after the expiration of the patent of the original research drug, and use new products to achieve corner overtaking, such as the carbetocin of Shengnuo Biotechtech.
Possess rich technology accumulation
Good performance growth
As one of the few domestic companies with peptide drug research and industrialization transformation capabilities, Shengnuo Biotech has a wealth of technology accumulation in the field of chemical synthesis of peptides. The company has mastered a number of independent core technologies for peptide synthesis and modification through independent research and development, and successfully solved the problem. The technical bottleneck for the large-scale production of multiple peptide API varieties.
The five core technicians of Shengnuo Biotechtechnology have more than 15 years of research and practical experience in the field of peptide synthesis. Among them, Mr. Wen Yongjun, the chief scientist and chairman of the company, is one of the earliest experts in the field of peptide drugs in China.
Shengnuo Biotech has 25 invention patents (1 of which also obtained international patents) and a large number of non-patent technologies, and has been awarded more than ten national and provincial scientific research and technological transformation projects.
The advantages of long-term technology accumulation in the field of peptides have enabled Shengnuo Bio to successfully develop multiple peptide APIs and preparations, and it has also made the company one of the few domestic companies that can undertake pharmaceutical research services for difficult peptide innovative drugs and customized production services for peptide products. , Using its own advanced process research and development and large-scale production capabilities to further improve profitability, and at the same time promote the industrial transformation of new peptide drugs in China.
During the reporting period, Shengnuo Biotechtech’s performance increased rapidly and the growth was good. From 2018 to 2020, the company’s operating income was 278 million yuan, 327 million yuan and 379 million yuan, respectively; net profits attributable to the parent were 30 million yuan, 48 million yuan and 60 million yuan, respectively.